T he extensively cited pooled analysis of the unconfounded randomised control trials of the treatment of hypertension 1 showed that a reduction in diastolic blood pressure of 5-6 mmHg maintained for a period of five years, was associated with a 38% reduction in the incidence of stroke and a 16% reduction in the incidence of coronary heart disease (CHD) events. From prospective observational studies, similar differences in diastolic blood pressure maintained over a more prolonged observation period would account for a 35-40% difference in stroke incidence and a 20-25% difference in coronary heart disease incidence. Thus it was concluded that there was a shortfall in coronary heart disease prevention observed in the intervention trials and several hypotheses were put forward to explain this lack of benefit. One such hypothesis propounded that the old drugs used in the trials, namely the diuretics and β-adrenoreceptor blocking drugs, although effective antihypertensive agents, were associated with long-term adverse metabolic side effects, the consequences of which could mitigate the beneficial effects of blood pressure lowering. Following on from this hypothesis was the suggestion that the more recently developed classes of drugs such as the angiotensin-converting-enzyme (ACE) inhibitors and the calcium channel blockers, by virtue of their absence of metabolic sequelae, might confer additional benefit in terms of coronary heart disease prevention when compared with older agents. Over recent years there has also been growing recognition of the importance of other peptidergic systems which are closely related to the activity of the renin-angiotensin-aldosterone system. The role of atrial natriuretic peptides and kinins particularly bradykinin, for example, remain controversial and only recently has insight been gained on the potential importance of the endothelins, some of the most potent naturally occurring vasoconstrictor substances yet identified.
Moreover, observations with these newer drugs in experimental models and selected subgroups of patients indicated the possibility of additional reductions in cardiovascular morbidity and mortality as a consequence of what has been termed 'tissue protection'. 2, 3 For a decade or more there has been an overriding demand to evaluate newer classes of drugs, including the ACE inhibitors, in hypertensive patients in order to establish whether or not these drugs confer greater protection against coronary heart disease, which is the most common complication of hypertension at least in northern European and American hypertensive populations. The objective for new outcome trials comparing different classes of drugs should therefore be to establish whether indeed there are additional benefits in terms of coronary heart disease prevention but it is noteworthy that most of the recently reported and ongoing trials in hypertension do not have CHD events as their primary endpoint but rather a combination of more generalised cardiovascular events, including stroke and myocardial infarction as their primary goal. 4 The consequence of this, to which I shall return later, is that many of these trials will be underpowered to resolve the issues over whether a particular drug or drug treatment regimen is more or less effective against protection against CHD. In the older randomised trials, 1 where drugs were compared with placebo, sustained differences in blood pressure enabled a few thousand patients to be studied with adequate power to look at differences in stroke incidence.
For ethical reasons it is no longer justified to undertake placebo-controlled trials in hypertension; where the primary endpoint is differences in coronary heart disease events and where equivalent blood pressure reductions are seen with different treatment strategies, studies require 9-10,000 patients per treatment arm to be adequately powered.
Two trials have recently reported comparing ACE inhibitor-based treatment with older drugs
The Captopril Prevention Project (CAPPP) 5 was the first study in hypertensive patients designed to compare conventional antihypertensive therapy with a regimen including an ACE inhibitor (captopril). In this study, 10,985 patients aged 25-66 years were randomly assigned to captopril or to conventional drugs (diuretics, β-blockers) and followed up for an average of approximately six years.The primary endpoint was a combination of fatal CHD and non-fatal myocardial infarction, stroke and other cardiovascular deaths.
The finding in this trial was that captoprilbased and conventional treatment did not differ in efficacy in preventing cardiovascular morbidity and mortality. However, on sub-group analysis there was a significantly increased stroke rate in There were a number of problems in the design and execution of this study, which should be viewed in conjunction with the interpretation of the results. First, the randomisation procedure used sealed envelopes rather than conventional randomisation by fax. The consequence of this procedure was that patients were not randomised properly, such that there were imbalances between the groups at baseline in terms of the type of patients in each group and in blood pressure. Despite adjustments for these baseline differences, the results of CAPPP have to be viewed within the limitations associated with observational rather than randomised trial data. Secondly, captopril was used in approximately 60% of the patients, in a once a day dose, which could easily explain the higher stroke rates in this group since they would have been on a relatively short acting drug with inadequate blood pressure control over the 24-hour period. Thirdly, and importantly, as stated above, there is no extant hypothesis that predicts an ACE inhibitor-based treatment strategy would be more effective than older drugs on the incidence of stroke and other cardiovascular events for an equivalent reduction in blood pressure. The CAPPP study was therefore not powered to address the question of whether ACE inhibitorbased treatment was better than conventional treatment in terms of prevention of CHD.
A second study (STOP-2) 6 attempted to address a similar question
This was a randomised trial in 6614 subjects aged 70-84 years with hypertension, who were randomly assigned to one of two newer drug classes -(the ACE inhibitors enalapril or lisinopril or the calcium channel blockers felodipine or isradipine) or to conventional drugs (β-blockers, diuretics). Following an average follow-up period of six years, there were no differences in the primary combined endpoint of fatal stroke, fatal myocardial infarction and other fatal cardiovascular diseases in the different treatment groups. In one of 48 retrospective statistical comparisons, the ACE inhibitor treatment group had significantly fewer myocardial infarctions (fatal CHD and non-fatal MI) than the calcium channel blocking drugs but the authors of this study appropriately draw attention to the interpretation with caution of this finding. Again, like CAPPP, the study was underpowered to address the question of whether newer treatments were more effective than older treatments in the prevention of CHD.
Thus on the basis of the randomised controlled trials of ACE inhibitors in hypertension, specifically in hypertensive patients to date, no definitive conclusions can be drawn with regard to their efficacy in the prevention of CHD.
There are many ongoing trials in hypertension comparing ACE inhibitors with older drugs, or ACE inhibitors with calcium channel blocking drugs, but only ALLHAT 7 and ASCOT 8 specifically address the question in relation to a primary endpoint of CHD events. In ALLHAT, ACE inhibitor-based treat-ment is compared with three other drug classes to which a variety of second line drugs are added and in ASCOT an older treatment combination (diuretic, β-blocker) is compared to a newer combination of treatments (calcium channel blocker, ACE inhibitor).
After reviewing the evidence, contemporary guidelines on hypertension management 7,8,9 recommend the use of ACE inhibitors for those patients in whom hypertension is associated with heart failure, left ventricular dysfunction or post myocardial infarction. They are also preferred therapy for Type 1 diabetes with proteinurea and hypertension. Further evidence, however, is required before than can be recommended as first line treatment for hypertensives with Type II diabetes.
Opportunity has been taken by the WHO/ISH to prospectively plan analyses of the collated trial data from over 30 trials and this exercise will, in addition, provide the necessary power to answer for once and for all whether blockade of the reninangiotensin-aldosterone system confers greater protection against CHD than other treatment strategies.
